Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Chiara Pellicano, Alessandra Oliva, Amalia Colalillo, Antonietta Gigante, Elisa D’Aliesio, Dania Al Ismail, Maria Claudia Miele, Rosario Cianci, Claudio Maria Mastroianni, Edoardo Rosato
{"title":"Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis","authors":"Chiara Pellicano, Alessandra Oliva, Amalia Colalillo, Antonietta Gigante, Elisa D’Aliesio, Dania Al Ismail, Maria Claudia Miele, Rosario Cianci, Claudio Maria Mastroianni, Edoardo Rosato","doi":"10.1007/s10238-024-01466-1","DOIUrl":null,"url":null,"abstract":"<p>Gastrointestinal (GI) tract involvement affects up to 90% of Systemic sclerosis (SSc) patients. The presence of GI symptoms is assessed by the University of California, Los Angeles, and Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0). Microbial translocation (MT) is reported in SSc patients consequently to increased intestinal permeability due to intestinal damage (ID) and dysbiosis. Aim of this study was to assess circulating levels of LBP and EndoCab IgM (markers of MT), IL-6 (marker of inflammation), I-FABP and Zonulin (markers of ID) in a cohort of SSc patients and healthy controls (HC). Moreover, we aimed to correlate these parameters with severity of GI symptoms. UCLA SCTC GIT 2.0 questionnaire was administered to 60 consecutive SSc patients. Markers of MT, inflammation and ID were evaluated in SSc patients and HC. SSc patients had higher median value of markers of MT, inflammation and ID than HC. The logistic regression analysis showed LBP as the only variable associated with an UCLA total score “moderate-to-very severe” [OR 1.001 (CI 95%: 1.001–1.002), <i>p</i> &lt; 0.001]. The logistic regression analysis showed LBP [OR 1.002 (CI 95%: 1.001–1.003), <i>p</i> &lt; 0.01] and disease duration [OR 1.242 (CI 95%: 1.023–1.506), <i>p</i> &lt; 0.05] as variables associated with UCLA distension/bloating “moderate-to-very severe”. The logistic regression analysis showed LBP as the only variable associated with UCLA diarrhea “moderate-to-very severe” [OR 1.002 (CI 95%: 1.001–1.003), <i>p</i> &lt; 0.01]. SSc patients with dysregulation gut mucosal integrity expressed by high levels of MT and ID biomarkers had more severe GI symptoms.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"3 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-024-01466-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Gastrointestinal (GI) tract involvement affects up to 90% of Systemic sclerosis (SSc) patients. The presence of GI symptoms is assessed by the University of California, Los Angeles, and Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0). Microbial translocation (MT) is reported in SSc patients consequently to increased intestinal permeability due to intestinal damage (ID) and dysbiosis. Aim of this study was to assess circulating levels of LBP and EndoCab IgM (markers of MT), IL-6 (marker of inflammation), I-FABP and Zonulin (markers of ID) in a cohort of SSc patients and healthy controls (HC). Moreover, we aimed to correlate these parameters with severity of GI symptoms. UCLA SCTC GIT 2.0 questionnaire was administered to 60 consecutive SSc patients. Markers of MT, inflammation and ID were evaluated in SSc patients and HC. SSc patients had higher median value of markers of MT, inflammation and ID than HC. The logistic regression analysis showed LBP as the only variable associated with an UCLA total score “moderate-to-very severe” [OR 1.001 (CI 95%: 1.001–1.002), p < 0.001]. The logistic regression analysis showed LBP [OR 1.002 (CI 95%: 1.001–1.003), p < 0.01] and disease duration [OR 1.242 (CI 95%: 1.023–1.506), p < 0.05] as variables associated with UCLA distension/bloating “moderate-to-very severe”. The logistic regression analysis showed LBP as the only variable associated with UCLA diarrhea “moderate-to-very severe” [OR 1.002 (CI 95%: 1.001–1.003), p < 0.01]. SSc patients with dysregulation gut mucosal integrity expressed by high levels of MT and ID biomarkers had more severe GI symptoms.

Abstract Image

评估系统性硬化症胃肠道受累情况的微生物转运和肠道损伤血清标志物
高达 90% 的系统性硬化症(SSc)患者会受到胃肠道受累的影响。胃肠道症状由加州大学洛杉矶分校和硬皮病临床试验联盟胃肠道量表(UCLA SCTC GIT 2.0)进行评估。据报道,由于肠道损伤(ID)和菌群失调导致肠道通透性增加,SSc 患者会出现微生物易位(MT)。本研究旨在评估一组 SSc 患者和健康对照组(HC)中 LBP 和 EndoCab IgM(MT 标记)、IL-6(炎症标记)、I-FABP 和 Zonulin(ID 标记)的循环水平。此外,我们还旨在将这些参数与消化道症状的严重程度联系起来。我们对 60 名连续的 SSc 患者进行了 UCLA SCTC GIT 2.0 问卷调查。对 SSc 患者和 HC 的 MT、炎症和 ID 标记进行了评估。与 HC 相比,SSc 患者的 MT、炎症和 ID 指标的中值更高。逻辑回归分析显示,枸杞痛是唯一与 UCLA 总分 "中度至非常严重 "相关的变量[OR 1.001 (CI 95%: 1.001-1.002),p < 0.001]。逻辑回归分析显示,枸杞痛[OR 1.002 (CI 95%: 1.001-1.003),p <0.01]和病程[OR 1.242 (CI 95%: 1.023-1.506),p <0.05]是与 UCLA 腹胀/腹胀 "中度至非常严重 "相关的变量。逻辑回归分析显示,枸杞多糖是唯一与加州大学洛杉矶分校腹泻 "中重度 "相关的变量[OR 1.002 (CI 95%: 1.001-1.003), p <0.01]。MT和ID生物标志物水平较高的SSc患者肠道粘膜完整性失调,其消化道症状更为严重。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Experimental Medicine
Clinical and Experimental Medicine 医学-医学:研究与实验
CiteScore
4.80
自引率
2.20%
发文量
159
审稿时长
2.5 months
期刊介绍: Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信